FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947605831> ?p ?o ?g. }

• W2947605831 abstract "Central venous catheter (CVC) placement increases the risk of thrombosis in people with cancer. Thrombosis often necessitates the removal of the CVC, resulting in treatment delays and thrombosis-related morbidity and mortality. This is an update of the Cochrane Review published in 2014.To evaluate the efficacy and safety of anticoagulation for thromboprophylaxis in people with cancer with a CVC.We conducted a comprehensive literature search in May 2018 that included a major electronic search of Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid), and Embase (Ovid); handsearching of conference proceedings; checking of references of included studies; searching for ongoing studies; and using the 'related citation' feature in PubMed. This update of the systematic review was based on the findings of a literature search conducted on 14 May 2018.Randomized controlled trials (RCTs) assessing the benefits and harms of unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), vitamin K antagonists (VKA), or fondaparinux or comparing the effects of two of these anticoagulants in people with cancer and a CVC.Using a standardized form, we extracted data and assessed risk of bias. Outcomes included all-cause mortality, symptomatic catheter-related venous thromboembolism (VTE), pulmonary embolism (PE), major bleeding, minor bleeding, catheter-related infection, thrombocytopenia, and health-related quality of life (HRQoL). We assessed the certainty of evidence for each outcome using the GRADE approach (Balshem 2011).Thirteen RCTs (23 papers) fulfilled the inclusion criteria. These trials enrolled 3420 participants. Seven RCTs compared LMWH to no LMWH (six in adults and one in children), six RCTs compared VKA to no VKA (five in adults and one in children), and three RCTs compared LMWH to VKA in adults.LMWH versus no LMWHSix RCTs (1537 participants) compared LMWH to no LMWH in adults. The meta-analyses showed that LMWH probably decreased the incidence of symptomatic catheter-related VTE up to three months of follow-up compared to no LMWH (risk ratio (RR) 0.43, 95% confidence interval (CI) 0.22 to 0.81; risk difference (RD) 38 fewer per 1000, 95% CI 13 fewer to 52 fewer; moderate-certainty evidence). However, the analysis did not confirm or exclude a beneficial or detrimental effect of LMWH on mortality at three months of follow-up (RR 0.82, 95% CI 0.53 to 1.26; RD 14 fewer per 1000, 95% CI 36 fewer to 20 more; low-certainty evidence), major bleeding (RR 1.49, 95% CI 0.06 to 36.28; RD 0 more per 1000, 95% CI 1 fewer to 35 more; very low-certainty evidence), minor bleeding (RR 1.35, 95% CI 0.62 to 2.92; RD 14 more per 1000, 95% CI 16 fewer to 79 more; low-certainty evidence), and thrombocytopenia (RR 1.03, 95% CI 0.80 to 1.33; RD 5 more per 1000, 95% CI 35 fewer to 58 more; low-certainty evidence).VKA versus no VKAFive RCTs (1599 participants) compared low-dose VKA to no VKA in adults. The meta-analyses did not confirm or exclude a beneficial or detrimental effect of low-dose VKA compared to no VKA on mortality (RR 0.99, 95% CI 0.64 to 1.55; RD 1 fewer per 1000, 95% CI 34 fewer to 52 more; low-certainty evidence), symptomatic catheter-related VTE (RR 0.61, 95% CI 0.23 to 1.64; RD 31 fewer per 1000, 95% CI 62 fewer to 51 more; low-certainty evidence), major bleeding (RR 7.14, 95% CI 0.88 to 57.78; RD 12 more per 1000, 95% CI 0 fewer to 110 more; low-certainty evidence), minor bleeding (RR 0.69, 95% CI 0.38 to 1.26; RD 15 fewer per 1000, 95% CI 30 fewer to 13 more; low-certainty evidence), premature catheter removal (RR 0.82, 95% CI 0.30 to 2.24; RD 29 fewer per 1000, 95% CI 114 fewer to 202 more; low-certainty evidence), and catheter-related infection (RR 1.17, 95% CI 0.74 to 1.85; RD 71 more per 1000, 95% CI 109 fewer to 356; low-certainty evidence).LMWH versus VKAThree RCTs (641 participants) compared LMWH to VKA in adults. The available evidence did not confirm or exclude a beneficial or detrimental effect of LMWH relative to VKA on mortality (RR 0.94, 95% CI 0.56 to 1.59; RD 6 fewer per 1000, 95% CI 41 fewer to 56 more; low-certainty evidence), symptomatic catheter-related VTE (RR 1.83, 95% CI 0.44 to 7.61; RD 15 more per 1000, 95% CI 10 fewer to 122 more; very low-certainty evidence), PE (RR 1.70, 95% CI 0.74 to 3.92; RD 35 more per 1000, 95% CI 13 fewer to 144 more; low-certainty evidence), major bleeding (RR 3.11, 95% CI 0.13 to 73.11; RD 2 more per 1000, 95% CI 1 fewer to 72 more; very low-certainty evidence), or minor bleeding (RR 0.95, 95% CI 0.20 to 4.61; RD 1 fewer per 1000, 95% CI 21 fewer to 95 more; very low-certainty evidence). The meta-analyses showed that LMWH probably increased the risk of thrombocytopenia compared to VKA at three months of follow-up (RR 1.69, 95% CI 1.20 to 2.39; RD 149 more per 1000, 95% CI 43 fewer to 300 more; moderate-certainty evidence).The evidence was not conclusive for the effect of LMWH on mortality, the effect of VKA on mortality and catheter-related VTE, and the effect of LMWH compared to VKA on mortality and catheter-related VTE. We found moderate-certainty evidence that LMWH reduces catheter-related VTE compared to no LMWH. People with cancer with CVCs considering anticoagulation should balance the possible benefit of reduced thromboembolic complications with the possible harms and burden of anticoagulants." @default.
• W2947605831 created "2019-06-07" @default.
• W2947605831 creator A5013491140 @default.
• W2947605831 creator A5024459640 @default.
• W2947605831 creator A5026324699 @default.
• W2947605831 creator A5041615321 @default.
• W2947605831 creator A5065403219 @default.
• W2947605831 creator A5071868716 @default.
• W2947605831 creator A5082149678 @default.
• W2947605831 creator A5084919462 @default.
• W2947605831 creator A5087847130 @default.
• W2947605831 creator A5090182271 @default.
• W2947605831 date "2018-06-01" @default.
• W2947605831 modified "2023-10-17" @default.
• W2947605831 title "Anticoagulation for people with cancer and central venous catheters" @default.
• W2947605831 cites W1491302080 @default.
• W2947605831 cites W1527739777 @default.
• W2947605831 cites W1531238400 @default.
• W2947605831 cites W1542673764 @default.
• W2947605831 cites W1555546082 @default.
• W2947605831 cites W1584405187 @default.
• W2947605831 cites W1595184853 @default.
• W2947605831 cites W1605667490 @default.
• W2947605831 cites W1634950970 @default.
• W2947605831 cites W1821404797 @default.
• W2947605831 cites W1920594391 @default.
• W2947605831 cites W1955610473 @default.
• W2947605831 cites W1963654054 @default.
• W2947605831 cites W1966988081 @default.
• W2947605831 cites W1968399105 @default.
• W2947605831 cites W1968407035 @default.
• W2947605831 cites W1969233851 @default.
• W2947605831 cites W1970675415 @default.
• W2947605831 cites W1971617338 @default.
• W2947605831 cites W1972167184 @default.
• W2947605831 cites W1972875444 @default.
• W2947605831 cites W1977083089 @default.
• W2947605831 cites W1980358129 @default.
• W2947605831 cites W1989844406 @default.
• W2947605831 cites W1990154448 @default.
• W2947605831 cites W1991658274 @default.
• W2947605831 cites W1992661527 @default.
• W2947605831 cites W1996156310 @default.
• W2947605831 cites W2001700757 @default.
• W2947605831 cites W2002698748 @default.
• W2947605831 cites W2007086823 @default.
• W2947605831 cites W2012934272 @default.
• W2947605831 cites W2013945874 @default.
• W2947605831 cites W2014412826 @default.
• W2947605831 cites W2026895719 @default.
• W2947605831 cites W2028608222 @default.
• W2947605831 cites W2030512823 @default.
• W2947605831 cites W2031184195 @default.
• W2947605831 cites W2033150840 @default.
• W2947605831 cites W2033377234 @default.
• W2947605831 cites W2034128870 @default.
• W2947605831 cites W2034850919 @default.
• W2947605831 cites W2040496666 @default.
• W2947605831 cites W2040586160 @default.
• W2947605831 cites W2040800118 @default.
• W2947605831 cites W2044889252 @default.
• W2947605831 cites W2044915940 @default.
• W2947605831 cites W2048778787 @default.
• W2947605831 cites W2052685518 @default.
• W2947605831 cites W2054724286 @default.
• W2947605831 cites W2057275729 @default.
• W2947605831 cites W2061227527 @default.
• W2947605831 cites W2064877577 @default.
• W2947605831 cites W2065378584 @default.
• W2947605831 cites W2066087069 @default.
• W2947605831 cites W2066221432 @default.
• W2947605831 cites W2068476516 @default.
• W2947605831 cites W2068579130 @default.
• W2947605831 cites W2083637906 @default.
• W2947605831 cites W2083815143 @default.
• W2947605831 cites W2085292470 @default.
• W2947605831 cites W2085354161 @default.
• W2947605831 cites W2085728164 @default.
• W2947605831 cites W2087617568 @default.
• W2947605831 cites W2087661939 @default.
• W2947605831 cites W2090476707 @default.
• W2947605831 cites W2102163277 @default.
• W2947605831 cites W2103419160 @default.
• W2947605831 cites W2104719354 @default.
• W2947605831 cites W2106763942 @default.
• W2947605831 cites W2107328434 @default.
• W2947605831 cites W2108811904 @default.
• W2947605831 cites W2109042377 @default.
• W2947605831 cites W2109612088 @default.
• W2947605831 cites W2112378432 @default.
• W2947605831 cites W2113020324 @default.
• W2947605831 cites W2115019673 @default.
• W2947605831 cites W2116041145 @default.
• W2947605831 cites W2117294447 @default.
• W2947605831 cites W2120092553 @default.
• W2947605831 cites W2120130633 @default.
• W2947605831 cites W2124101267 @default.
• W2947605831 cites W2125435699 @default.
• W2947605831 cites W2129538099 @default.
• W2947605831 cites W2132381095 @default.

• next